FBIO Stock Analysis: Buy, Sell, or Hold?
FBIO - Fortress Biotech, Inc.
$2.87
0.10 (3.61%)
▲
5d:
-2.05%
30d:
-16.33%
90d:
+3.24%
HOLD
MODERATE Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 13, 2026
0d
Get Alerted When FBIO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: FBIO shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: FBIO shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
In-depth Analysis How we analyze
Valuation Analysis: FBIO is currently trading at $2.87, which is considered slightly low relative to its 30-day fair value range of $2.82 to $3.48. From a valuation perspective, the stock is trading at a discount (Forward PE: -5.7) compared to its historical average (136.2). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, FBIO is in a strong uptrend. Immediate support is located at $2.57, while resistance sits at $3.06. The stock is showing strong short-term momentum, up 3.6% recently.
Market Sentiment: The stock scores a mixed 55/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $11.00 (+283.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, FBIO is in a strong uptrend. Immediate support is located at $2.57, while resistance sits at $3.06. The stock is showing strong short-term momentum, up 3.6% recently.
Market Sentiment: The stock scores a mixed 55/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $11.00 (+283.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$2.82 -
$3.48
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
89.0%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.6%)
- BULLISH: Trading 283.3% below Wall St target ($11.00)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- NEUTRAL: Bottoming setup forming (55/100) — watch for confirmation
Trading Range Analysis
30-Day Trading Range
$2.82 -
$3.48
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$2.57
Resistance Level
$3.06
Current Trend
Strong Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.74
Wall Street Target
$11.00
(+283.3%)
Revenue Growth (YoY)
14.0%
Profit Margin
163.3%
PE vs Historical
-5.7 vs 136.2
CHEAP
Share & Embed Analysis
Last updated: August 24, 2026 4:35 AM ET
Data refreshes hourly during market hours. Next update: 5:35 AM
Data refreshes hourly during market hours. Next update: 5:35 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is FBIO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 42 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 66 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$35 | 50 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$108 | 52 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$127 | 41 HOLD |
